Colgate-Palmolive Management
Management criteria checks 4/4
Colgate-Palmolive's CEO is Noel Wallace, appointed in Jul 2018, has a tenure of 8.08 years. total yearly compensation is $16.48M, comprised of 9.1% salary and 90.9% bonuses, including company stock and options. directly owns 0.059% of the company’s shares, worth $43.17M. The average tenure of the management team and the board of directors is 2.6 years and 7.4 years respectively.
Key information
Noel Wallace
Chief executive officer
US$16.5m
Total compensation
| CEO salary percentage | 9.10% |
| CEO tenure | 8.1yrs |
| CEO ownership | 0.06% |
| Management average tenure | 2.6yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
Narrative Update • Aug 04
CL: International Execution And Pet Nutrition Will Offset 2026 Margin Pressures
Analysts have nudged their fair value estimate for Colgate-Palmolive higher from about $96.68 to roughly $98.95. This reflects updated price targets that highlight solid profit execution, resilient international growth and model tweaks after recent quarterly results.
New Narrative • Aug 03
The Ten Percent Margin Is A Write Down, Not The Business
Generated used Opus 5. Not the opinion of the author.Seeking Alpha • Jul 31
Colgate-Palmolive: Steady Globally, Weak Domestically
Summary Colgate-Palmolive Company reported stable overall Q2 results. Organic revenues grew moderately, and margins stayed good. Growth varies by market. CL's advertising investments are yielding results in Latin America and Asia Pacific, but competitive pressure is weakening results in North America. I estimate CL stock to have a fair value of $92.4. Read the full article on Seeking AlphaNarrative Update • Apr 09
CL: 2030 Plan Execution And Margins Will Shape 2026 Setup
Analysts have trimmed the Colgate-Palmolive fair value estimate by about $0.58 to $96.68, reflecting slightly softer revenue growth assumptions, a modestly lower future P/E, and mixed recent research that includes both reduced price targets and an upgrade tied to confidence in the 2030 plan and ongoing margin resilience. Analyst Commentary Recent Street research on Colgate-Palmolive shows a mix of optimism around the long-term plan and caution around nearer term cost and valuation risks.Narrative Update • Mar 25
CL: 2030 Plan And Emerging Markets Execution Will Shape 2026 Setup
Colgate-Palmolive's fair value estimate edges up to $97.26 from $97.21 as analysts lift price targets toward the $100 to $105 range, citing stronger confidence in the 2030 plan, product innovation, and emerging markets execution. Analyst Commentary Recent Street research on Colgate-Palmolive clusters around higher price targets and upgraded ratings, with the fair value conversation increasingly framed around the 2030 plan, execution in emerging markets, and portfolio moves such as the exit from private label pet food.Narrative Update • Mar 10
CL: 2030 Plan And Emerging Markets Support Measured 2026 Execution Setup
Analysts have nudged their price expectations for Colgate-Palmolive higher, with the updated fair value estimate moving from about $96.68 to roughly $97.21. They cite growing confidence in the company’s 2030 plan, product innovation efforts and emerging markets exposure, as reflected in a series of recent price target increases across major firms.Narrative Update • Feb 24
CL: 2030 Plan And Emerging Markets Will Drive Balanced 2026 Setup
Analysts have raised their implied price target for Colgate-Palmolive by about $8 to reflect higher conviction in the company’s 2030 plan, product innovation pipeline and emerging market exposure, as well as refreshed views on sector valuations. Analyst Commentary Recent research has centered on how Colgate-Palmolive’s 2030 plan, product pipeline and emerging market footprint feed into both growth potential and current valuation.Analysis Article • Feb 06
There May Be Some Bright Spots In Colgate-Palmolive's (NYSE:CL) Earnings
Colgate-Palmolive Company's ( NYSE:CL ) recent soft profit numbers didn't appear to worry shareholders, as the stock...Narrative Update • Jan 28
CL: Emerging Markets And 2026 Setup Will Shape Balanced Risk Reward
Analysts have nudged their price targets for Colgate-Palmolive higher, reflected in a modest fair value move from about $87.47 to $88.89. They are factoring in slightly stronger revenue growth assumptions, a marginally higher future P/E and recent rating and target changes across firms such as Barclays, JPMorgan, UBS, Wells Fargo, Piper Sandler and TD Cowen.Narrative Update • Jan 10
CL: Emerging Markets And 2026 Setup Support Balanced Outlook After Recent Softness
Our updated analyst price target for Colgate-Palmolive edges up to about US$87.47 from roughly US$87.21, as analysts balance slightly softer modeled revenue growth with modestly higher profit margin and future P/E assumptions. This view is supported by recent research that pairs cautious consumer staples outlooks with a more positive stance on the company’s emerging markets exposure and potential 2026 acceleration.Narrative Update • Dec 15
CL: Emerging Market Strength Will Support Gradual Recovery As Q3 Softness Fades
Analysts have trimmed their price target on Colgate-Palmolive to $87 from the low-to-mid $90s, reflecting near term softness in Q3 results and muted personal care growth, even as they expect organic sales momentum to gradually improve. Analyst Commentary Analysts remain divided on Colgate-Palmolive, with recent target cuts reflecting near term execution risk, while longer term growth and margin recovery expectations stay largely intact.Narrative Update • Nov 30
CL: Gradual Recovery Expected As Temporary Headwinds Ease In Personal Care Markets
Narrative Update on Colgate-Palmolive Colgate-Palmolive's analyst price target has been modestly reduced by $0.05 to $87.21. Analysts cite near-term growth challenges and muted sector outlooks following a soft Q3, but expect gradual improvement as temporary pressures ease.Narrative Update • Nov 16
CL: Organic Sales Momentum Will Rebound As Near-Term Headwinds Ease
Colgate-Palmolive's analyst consensus price target was revised downward from approximately $88.84 to $87.26. Analysts cite a soft third quarter, moderated growth expectations, and ongoing category headwinds as key factors behind the adjustment.Narrative Update • Nov 02
CL: Future Cost Optimization Will Drive Competitive Advantage Amid Category Headwinds
Colgate-Palmolive’s fair value estimate has been reduced from $90.74 to $88.84 per share. Analysts cite persistent category headwinds and a moderated sales outlook as factors behind lower price targets across the sector.Narrative Update • Oct 18
Emerging Markets And Digital Transformation Will Unlock Global Value
Colgate-Palmolive's analyst fair value price target has decreased from $93.11 to $90.74. Analysts cite lowered sales guidance, persistent category headwinds, and muted growth outlooks as key factors behind their revised estimates.Narrative Update • Oct 03
Emerging Markets And Digital Transformation Will Unlock Global Value
Colgate-Palmolive's analyst price target has been revised downward by approximately $2 to $93. Analysts cite ongoing category headwinds and decelerating growth in the personal care sector as reasons for this adjustment.Analysis Article • Sep 30
There's Reason For Concern Over Colgate-Palmolive Company's (NYSE:CL) Price
Colgate-Palmolive Company's ( NYSE:CL ) price-to-earnings (or "P/E") ratio of 22.3x might make it look like a sell...Seeking Alpha • Apr 22
A Historic Brand, A Fresh Approach: Inside Colgate-Palmolive's Machine
Summary Colgate-Palmolive achieved over $20 billion in revenue in 2024, driven by strong brand identity, operational discipline, and a diversified product portfolio across Oral Care, Personal Care, Home Care, and Pet Nutrition. The company maintained profitability despite inflation, with a 14.4% margin, and continued to invest in marketing and R&D, enhancing brand differentiation and price stability. Financially robust, Colgate-Palmolive showed significant revenue and margin growth, generating record free cash flow, and is well-positioned for 2025 with a "Buy" rating and a target share price of $100.08. Key risks include currency fluctuations, raw material costs, and competition, but strong daily demand for products and innovation in high-growth segments like Pet Nutrition support long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Mar 20
Colgate-Palmolive: A Defensive Stock With Growth Potential
Summary Colgate-Palmolive is one of the leaders in the global toothpaste market. On January 31, Colgate-Palmolive released financial results that left me with mixed reactions. Demand for its products in Latin America is growing rapidly, but the strengthening of the US dollar has not allowed Colgate-Palmolive to fully reflect this in its EPS. In this article, you, Seeking Alpha readers, will learn why, according to my "ALLKA 4D Rating" model, Colgate-Palmolive is a stock with an attractive risk/reward ratio. Read the full article on Seeking AlphaSeeking Alpha • Mar 14
Is Colgate-Palmolive Quietly Building The Next Pet Food Empire?
Summary Colgate-Palmolive's premiumization strategy and pet nutrition expansion offer significant growth potential, with a price target of $115 per share, suggesting a 26% upside. Despite high valuation metrics, CL's superior profitability, high margins, and exceptional cash flow justify its premium valuation and long-term investment appeal. The company's strong pricing power, particularly in premium oral care and pet food, positions it well against inflation and competitive pressures. Risks include potential valuation compression and competition in pet nutrition, but CL's consistent cash flow and brand strength mitigate these concerns. Read the full article on Seeking AlphaSeeking Alpha • Feb 25
Colgate-Palmolive: Don't Get Your Hopes Up (Yet)
Summary After a strong first half of 2024, Colgate-Palmolive's stock continues to be an underperformer in the consumer staples sector. The stock is trading at a discount to the level implied by current margins, but there is a good reason for that. Margins are likely to come under pressure in 2025 and from a dividend point of view, CL also appears unattractive at the moment. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
Colgate-Palmolive Stock: Post-Earnings Drop Isn't A Buy-The-Dip Moment
Summary Toothpaste and manual toothbrushes market leader Colgate-Palmolive Company released its fourth quarter and full-year 2024 results today. Judging by the share price reaction, and considering CL stock is down more than 20% from its all-time high, this clearly looks like a “buy the dip” moment. However, I'll explain why I don't think it's a good idea to buy CL shares, either for dividend or total return investors, and despite the company's undoubtedly solid 2024 performance. Read the full article on Seeking AlphaSeeking Alpha • Dec 17
Colgate-Palmolive: Digital Advertising Is The Base From Which To Start Again
Summary Colgate-Palmolive's (CL) revenue growth has been minimal over the past decade, with a CAGR of only 1.53%, not even keeping pace with inflation. Despite a 61-year streak of increasing dividends, CL's EPS growth has been stagnant, leading to a higher payout ratio. Increased advertising expenditures, particularly in digital, have shown higher ROI than traditional channels. CL's future growth may hinge on digital advertising and expanding into Personal and Home Care markets, but the current valuation is too high for a buy rating. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Colgate-Palmolive: Approaching Buy Territory With Some Important Catalysts
Summary As expected, Colgate-Palmolive's stock has retreated from its recent highs over the past few months. Upside potential for 2025 remains limited as gross margin tailwinds are fading. Nonetheless, there are some key areas that investors should keep a close eye on over the course of next year. Read the full article on Seeking AlphaSeeking Alpha • Oct 25
Colgate-Palmolive Q3: Great Company, But Not Enough To Warrant A Position Now
Summary Colgate-Palmolive Company's Q3 earnings showed mixed results, with revenue and EPS beating estimates but North America and Latin America sales declining, leading to a 3% stock drop. The company's improved gross margins and increased advertising spend are positive signs, but the market remains concerned about regional sales declines. The Pet Nutrition segment shows strong growth potential, driven by the pet humanization trend, and could be a key revenue catalyst. Given macroeconomic uncertainties and regional performance, I rate Colgate-Palmolive stock as a hold, awaiting further developments in NA, LatAm, and Pet Nutrition segments. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$2b |
| Mar 31 2026 | n/a | n/a | US$2b |
| Dec 31 2025 | US$16m | US$2m | US$2b |
| Sep 30 2025 | n/a | n/a | US$3b |
| Jun 30 2025 | n/a | n/a | US$3b |
| Mar 31 2025 | n/a | n/a | US$3b |
| Dec 31 2024 | US$18m | US$2m | US$3b |
| Sep 30 2024 | n/a | n/a | US$3b |
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$3b |
| Dec 31 2023 | US$17m | US$1m | US$2b |
| Sep 30 2023 | n/a | n/a | US$2b |
| Jun 30 2023 | n/a | n/a | US$1b |
| Mar 31 2023 | n/a | n/a | US$2b |
| Dec 31 2022 | US$14m | US$1m | US$2b |
| Sep 30 2022 | n/a | n/a | US$2b |
| Jun 30 2022 | n/a | n/a | US$2b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$15m | US$1m | US$2b |
| Sep 30 2021 | n/a | n/a | US$3b |
| Jun 30 2021 | n/a | n/a | US$3b |
| Mar 31 2021 | n/a | n/a | US$3b |
| Dec 31 2020 | US$14m | US$1m | US$3b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$3b |
| Mar 31 2020 | n/a | n/a | US$3b |
| Dec 31 2019 | US$11m | US$1m | US$2b |
Compensation vs Market: Noel's total compensation ($USD16.48M) is about average for companies of similar size in the US market ($USD14.46M).
Compensation vs Earnings: Noel's compensation has been consistent with company performance over the past year.
CEO
Noel Wallace (62 yo)
8.1yrs
Tenure
US$16,478,196
Compensation
Mr. Noel R. Wallace serves as Chief Executive Officer and Director of Colgate-Palmolive Company since April 2, 2019 and has been its President since July 11, 2018. Mr. Wallace serves as Chairman of Colgate...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 8.1yrs | US$16.48m | 0.059% $ 43.2m | |
| Chief Financial Officer | 5.8yrs | US$5.66m | 0.0075% $ 5.5m | |
| COO of Global Customer Dev. | 7yrs | US$4.08m | 0.010% $ 7.3m | |
| Chief Operating Officer of Americas | 1.2yrs | US$11.92m | 0.0088% $ 6.4m | |
| Chief Technology Officer | 3.9yrs | no data | no data | |
| Chief Information Officer | 3.6yrs | no data | no data | |
| Chief Investor Relations Officer and Executive VP of M&A | less than a year | no data | no data | |
| EVP, Chief Legal Officer & Secretary | less than a year | no data | 0.0029% $ 2.2m | |
| Executive Vice President of Internal Audit & Compliance | 1.6yrs | no data | no data | |
| Chief Communications Officer | 1.4yrs | no data | no data | |
| Chief Marketing Officer | less than a year | no data | no data | |
| Chief People Officer | 6.6yrs | no data | 0.0027% $ 2.0m |
2.6yrs
Average Tenure
58yo
Average Age
Experienced Management: CL's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 7.3yrs | US$16.48m | 0.059% $ 43.2m | |
| Independent Director | 20.8yrs | US$315.68k | 0.0046% $ 3.4m | |
| Independent Director | 10.4yrs | US$313.16k | 0.0031% $ 2.3m | |
| Independent Director | 7.4yrs | US$300.31k | 0.0016% $ 1.2m | |
| Lead Independent Director | 10.9yrs | US$336.18k | 0.00011% $ 80.6k | |
| Independent Director | 6.4yrs | US$315.41k | 0.00035% $ 256.6k | |
| Independent Director | 11.4yrs | US$315.68k | 0.00074% $ 542.4k | |
| Independent Director | 5.4yrs | US$308.41k | 0.00040% $ 293.2k | |
| Independent Director | less than a year | no data | 0.00017% $ 124.6k | |
| Independent Director | 2.4yrs | US$308.31k | 0.00072% $ 527.8k |
7.4yrs
Average Tenure
65yo
Average Age
Experienced Board: CL's board of directors are considered experienced (7.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/16 14:38 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Colgate-Palmolive Company is covered by 42 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Graja | Argus Research Company |
| Lauren Lieberman | Barclays |
| Fulvio Cazzol | Berenberg |